ICER Determines OCA’s Benefit In NASH Might Support Limited Approval

 
• By Joseph Haas

The cost-effectiveness watchdog group sees the fibrosis benefit with Intercept’s obeticholic acid as supporting use in sicker NASH patients, but its overall risk-benefit ratio doesn’t merit broader use.

Businessman balancing between cost and benefit in business conce
ICER says OCA's risk-benefit ratio might only support use in sicker patients

More from Drug Pricing

More from Scrip